SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma offers to buy remaining stake in Taro

19 Oct 2011 Evaluate

Sun Pharmaceutical, which had initiated acquisition of Taro Pharmaceutical Industries four-and-a-half years ago, made a proposal to be the 100 per cent owner of the West Asian drug company. After about three years of legal battle, Sun had in last September completed the acquisition of controlling stake in the Israeli firm. Today, Sun Pharma, the country’s largest drugmaker by market cap, owns 66 per cent in Taro.Sun has offered to buy all of the outstanding shares it does not own in Taro — for $24.40 a share. Tts offer represents 25.96 per cent premium over the most recent closing of the Israeli firm's common stock. The offer is subject to the approval of Taro Board and other regulatory authorities.

Sun Pharma Inds. Share Price

1874.00 26.70 (1.45%)
11-May-2026 13:46 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1874.00
Dr. Reddys Lab 1295.00
Cipla 1321.95
Zydus Lifesciences 946.80
Lupin 2271.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×